Article

LO7 : A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patients

2015-04-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f4f5d48e-d445-5e47-8d49-ba2a4c80b418
DOI: 10.1016/s0168-8278(15)30153-7

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

LO7 : A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patientsDOI 10.1016/s0168-8278(15)30153-7Read

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.Semantic proximity Read

58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTIONSemantic proximity Read

Treatment of HCV infection by targeting microRNA.Semantic proximity Read

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.Semantic proximity Read

Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitorsSemantic proximity Read

Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus InfectionSemantic proximity Read

Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapySemantic proximity Read

Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patientsSemantic proximity Read

Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.Semantic proximity Read

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.Semantic proximity Read

Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection.Semantic proximity Read

Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.Semantic proximity Read